RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Sivaraman, V., Richey, M. M., & Nasir, A. B. M. (2021). Alcohol, cannabis and crossfading: Concerns for COVID-19 disease severity. Biology, 10(8), Article 779. https://doi.org/10.3390/biology10080779
Simple Summary Heavy alcohol and cannabinoid consumption prior to pneumonia infection resulted in an increased severity of disease in mice. Analysis of hospital discharge data showed an increased length of stay among alcohol-consuming pneumonia patients. Increased alcohol and cannabis sales during the early months of 2020 suggest that consumption of both substances has increased significantly during the pandemic, potentially representing an increased risk of severe COVID-19 mediated by lung inflammation. Risk factors for severe COVID-19 pathology are currently being investigated worldwide. The emergence of this highly infectious respiratory disease has plagued the world, with varying severity across populations of different age, race, and socio-economic level. These data suggest that other environmental or social factors may contribute to this disease's severity. Using a mouse model, we identify heavy alcohol and cannabinoid consumption as risk factors for increased pulmonary pathology in the setting of exposure to a microbial pulmonary pathogen (K. pneumoniae). We present observational evidence that pneumonia patients admitted to North Carolina hospitals have longer lengths of stay when they endorse alcohol use or have conditions considered alcohol attributable. We are concerned that the observed increase in alcohol and legal cannabinoid sales during lockdown and quarantine may contribute to increased pulmonary pathology among patients who become infected with COVID-19.